Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Paratek Pharmaceuticals Inc (PRTK) is Surging

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) shares have surged over 30% in after-hours after the company reported positive results from a phase 3 study of Omadacycline in community-acquired bacterial pneumonia. Specifically, Omadacycline met all FDA primary and secondary endpoints and EMA co-primary endpoints, and the drug candidate was generally safe and well tolerated. Due to the data, a U.S. NDA is planned as early as the first quarter of 2018.

CEO and Chairman Michael Bigham said:

This successful study demonstrates the potential of omadacycline to treat community-acquired bacterial pneumonia, a significant and serious health issue. This Phase 3 study in pneumonia along with our previously announced successful Phase 3 study in skin infections satisfy the regulatory filing requirements of our special protocol assessment with the FDA. We look forward to sharing these data with the FDA and EMA. Our plan is to submit our NDA in the U.S. as early as the first quarter of 2018 with an EMA submission later in 2018.

Community acquired bacterial pneumonia is a major problem, resulting in 3.3 million hospitalizations in the U.S. alone each year, with a mortality risk of over 5% in observational studies.

What Does The Smart Money Sentiment Say?

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

According to our data, the smart money was relatively bullish in the fourth quarter. Of the 742 elite funds we track, 19 funds owned $78.45 million of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) and accounted for 22.50% of the float on December 31, an increase from 17 funds and $63.71 million respectively on September 30. Seth Klarman‘s Baupost Group was one of the bulls, having reported a stake of 2.04 million shares at the end of 2016.

The Bottom Line

Given the need to successfully treat community-acquired  bacterial pneumonia, traders have bid up Paratek Pharmaceuticals Inc (NASDAQ:PRTK) after results from a phase 3 study showed that the company’s lead drug candidate, Omadacycline, had met its primary and secondary endpoints and was generally safe as well. For another interesting read, check out the 10 least addictive drugs.

Follow Paratek Pharmaceuticals Inc. (NASDAQ:PRTK)
Trade (NASDAQ:PRTK) Now!

Disclosure:None

Wall Street Bull

Wall Street Bull